• Foundation of the „CECOG Academy“

    Foundation of the „CECOG Academy“

    CECOG is proud to announce the foundation of the CECOG Academy as of July 19, 2017.

    Under the roof of the newly founded „CECOG Academy“, the abundance of all educational activities hitherto conducted by CECOG will be united.

    Read more →
  • CECOG Immuno – Oncology Training  29.-30. September

    CECOG Immuno – Oncology Training 29.-30. September

    Sponsored with a Grant of Merck Sharp & Dohme and Astra Zeneca. If you are interested please send an e-mail to [email protected]

    Venue: Hotel de France, Schottenring 3, 1010 Vienna
    Language: English

    PDF Download: Agenda
    PDF Download: Registration Form

    Read more →
  • CECOG Restructuring

    CECOG is pleased to announce the promotion of Dr. Christiane Thallinger to its Chief Executive Officer (CEO). Dr. Christiane Thallinger holds university degrees as MD, MSc and MBA and is thus highly qualified for the position of CECOG’s CEO. There is no doubt, that Dr. Thallinger will excellently contribute to the further expansion of CECOG.

    Read more →
  • CECOG Proudly Announces Important Honors Awarded to its President

    As a result of CECOG activities, its President, Prof. Zielinski, has recently received two important honors related to CECOG’s activities in Central and Southeastern Europe: Prof. Zielinski was awarded the Honorary Membership of the Polish Society of Medical Oncology from the outgoing president of the society, Prof. Maciej Krzakowski during its recent meeting in Gdansk

    Read more →
  • CECOG to launch Lung Cancer Initiative in Central and Southeastern Europe

    CECOG is launching a vigorous initiative on diagnostic tools and subsequent treatment in Central and Southeastern Europe with a kick-off meeting planned during the upcoming ESMO Annual Meeting followed by an even broader initiative during the World Conference on Lung Cancer in Vienna in December 2016. Stay put for further information on outcomes.

    Read more →
  • Final Results of the CECOG TURANDOT Study published

    The final results of the CECOG TURANDOT Randomized Phase III Study were published in „Lancet Oncology“ recently Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S,

    Read more →

CECOG Facts & Figures

Summer School